Full text is available at the source.
Abstract
ISL-3C-LNPs demonstrated high mRNA encapsulation and delivery efficiency.
- Traditional lipid nanoparticles face challenges in liver-targeted transfection and cellular immune response activation.
- CS22021-based ISL-3C-LNPs enable localized mRNA delivery at the injection site after intramuscular administration.
- These LNPs may offer a better safety profile due to their localized delivery.
- The CS22021-based formulation efficiently delivers a varicella-zoster virus mRNA vaccine, producing strong immune responses.
- A significantly higher CD8T cell response is associated with the CS22021-based ISL-3C-LNP compared to conventional LNP formulations.
Simplified